Stay updated on MAPP2 MDMA Therapy Clinical Trial

Sign up to get notified when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPP2 MDMA Therapy Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The page now shows a new revision label v3.6.3, replacing the previous v3.6.2.
    Difference
    0.0%
    Check dated 2026-07-04T10:08:57.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.0 to v3.6.2, signaling a small software update to the ClinicalTrials.gov page. No study data, content, or details appear to be changed as part of this update.
    Difference
    0.0%
    Check dated 2026-06-27T05:58:39.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The page adds new participant-focused sections (How to Read a Study Record, Common Questions, How to Join a Study) and marks recruitment as No longer looking for participants. The Intervention/Treatment label is updated and the revision tag advances to v3.6.0, replacing v3.5.5.
    Difference
    0.4%
    Check dated 2026-06-13T04:45:27.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The page shows Revision: v3.5.5, replacing v3.5.4, indicating a small update to the study record's metadata rather than substantive content changes.
    Difference
    0.0%
    Check dated 2026-06-05T22:49:52.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The study record version was updated from v3.5.3 to v3.5.4, representing a minor maintenance update to the ClinicalTrials.gov page. This change does not alter the study design, endpoints, eligibility criteria, or reported information.
    Difference
    0.0%
    Check dated 2026-05-15T15:54:39.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The sponsor line now shows Resilient Pharmaceuticals as sponsor and responsible party, replacing Lykos Therapeutics. This change reflects a shift in the organization overseeing the study.
    Difference
    0.2%
    Check dated 2026-05-01T09:22:58.000Z thumbnail image

Stay in the know with updates to MAPP2 MDMA Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPP2 MDMA Therapy Clinical Trial page.